CS b-Bioactive®, Bioiberica’s Chondroitin Sulfate, has widely demonstrated to be effective for pain relief and improvement of functional disability in patients with osteoarthritis. Moreover, it has also demonstrated to slow-down the progression of the disease.

Latest randomized clinical trials confirmed the efficacy of CS b-Bioactive®.

The importance of these clinical trials lies in that they demonstrate objectively and through innovative techniques the efficacy of CS b-Bioactive® in the treatment of osteoarthritis.

CS b-Bioactive® Reduces Brain Response to Knee Pain

A recent randomized, double-blind clinical trial showed that CS b-Bioactive® attenuates brain response to painful stimulus on the knee in patients with osteoarthritis.

This interesting study, developed in the Rheumatology Department and the MRI Research Unit of the Hospital del Mar in Barcelona is a randomized, double-blind clinical trial in which 64 knee osteoarthritis patients received CS b-Bioactive® chondroitin sulfate 800 mg/day or placebo for a 4-month treatment course.

Patients were assessed at baseline and post-treatment by applying painful pressure on the patella surface and on the knee medial interline, during the acquisition of two fMRI sequences. The main outcome measurement was attenuation of the response evoked by knee painful stimulation in the pain-processing brain system. fMRI has proven its ability to comprehensively map brain activity associated with pain experience.

fMRI of patella pain, showed a larger activation reduction in the CS b-Bioactive® group than in placebo in key regions of pain-processing network.

These results confirmed the analgesic effect of CS b-Bioactive® on knee pain, assessed by an objective imaging technique as fMRI. The observed positive treatment effect of CS b-Bioactive® chondroitin sulfate is consistent with the known chondroitin action on cartilage protection due to chondrocyte regeneration.
Results from this randomized double-blind placebo-controlled clinical trial confirm the disease-modifying effect of CS b-Bioactive® by means of nuclear magnetic resonance (MRI).

These results are very important because this is the first time that the disease-modifying effect has been demonstrated using a technique as objective as MRI, with visible results after six months of treatment. Previously, the technique used had always been X-rays, which is much less objective and precise than MRI.

The randomized, double-blind, placebo-controlled clinical trial was done on 69 patients with knee OA and synovitis who received 800 mg of CS b-Bioactive® chondroitin sulfate or a placebo for 12 months.

The results show that patients treated with CS b-Bioactive® experienced a reduction in the loss of cartilage volume in the lateral femorotibial compartment compared to placebo and a reduction in subchondral bone lesions compared to placebo.

CS b-Bioactive® achieved a 60% reduction in the rate of cartilage volume loss compared to placebo at 6 months and a 70% reduction at 12 months.

About CS b-Bioactive®

CS b-Bioactive® is the most thoroughly researched chondroitin sulfate on the market. Its efficacy and safety has been tested in 20 clinical studies and more than 5,000 patients. CS b-Bioactive® is researched and manufactured by Bioiberica, the global leader in joint health.


New Clinical Data